Oxford Biomedica ups revenue forecast as AstraZeneca lifts vaccine output
AstraZeneca
12,018.00p
16:25 25/04/24
5.87%
666.00p
Gene and cell therapy group Oxford Biomedica on Tuesday doubled annual earnings guidance after pharmaceutical giant AstraZeneca ordered more Covid-19 vaccines.
FTSE 100
8,077.17
16:25 25/04/24
n/a
n/a
FTSE 250
19,595.98
16:25 25/04/24
n/a
n/a
FTSE 350
4,433.35
16:25 25/04/24
n/a
n/a
FTSE All-Share
4,387.01
16:25 25/04/24
n/a
n/a
Oxford Biomedica
217.50p
16:24 25/04/24
-0.46%
-1.00p
Pharmaceuticals & Biotechnology
22,739.40
16:25 25/04/24
3.84%
841.90
Oxford Biomedica, which has an 18-month supply deal with AstraZeneca to make its AZD1222 vaccine, lifted forecasts for expected cumulative revenues to more than £100m by end-2021 from more than £50m.
As a result, Oxford Biomedica said it expected 'significant growth' in annual operating earnings for the year to end-December.